In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
More than 173,000 women in the United States are living with metastatic breast cancer and each has a story to tell. AstraZeneca is launching a nationwide photo-sharing campaign to provide them another way to share their inspiration, experiences and strengths with others.
To show their support, women living with metastatic breast cancer can upload photos of themselves on social media using the campaign hashtag #MBCStrength. Photos posted on Twitter by October 1, 2014 and tagged with #MBCStrength will be considered for a Times Square display in New York City on the fifth anniversary of Metastatic Breast Cancer Awareness Day on October 13, 2014.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7305551-mymbcstory-astrazeneca-encourages-women-with-metastatic-breast-cancer-to-share/
During a live global event, Elekta announced the launch of Versa HD™, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60246-elekta-sets-new-benchmark-for-cancer-treatment-launch-of-versa-hd-system
CVS Health, the nation’s largest pharmacy innovation company, today launched an in-store fundraising campaign at CVS Pharmacy locations nationwide to benefit the American Lung Association’s LUNG FORCE initiative which aims to make lung cancer, the leading cancer killer of women in the United States, a public health priority.
Now through June 11, customers can donate $1, $3 or more at the register at 7,900 CVS Pharmacy locations and online at www.cvs.com/lung (all proceeds will support the initiative). CVS Health is the national presenting sponsor of LUNG FORCE, which is focused on raising awareness about lung cancer in women, and increasing research funding to save lives.
To view the multimedia release go to:
http://www.multivu.com/players/English/7817251-cvs-health-lung-force-fundraiser/
During the month of November, VPI, a Nationwide company, will donate $5 to the Animal Cancer Foundation (ACF), up to $10,000, for every photo, story or statistic shared on Facebook, Twitter, and Instagram using #CurePetCancer. For more information, visit www.curepetcancer.com. To date, VPI has raised nearly $200,000 to benefit the ACF.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7361751-veterinary-pet-insurance-teams-with-animal-cancer-foundation-for-national-pet-cancer-awareness-month/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
With September marking National Prostate Cancer Awareness Month and the kick-off of the 2015 NFL season, the Urology Care Foundation and the NFL have renewed their commitment to driving prostate health awareness, as well as teamed up to highlight a Public Service Announcement (PSA) focused on educating men about prostate cancer and encouraging them to take charge of their health through the Know Your Stats® campaign.
The Know Your Stats® campaign is a rallying force to connect, educate and inspire men across the country to know their prostate cancer risk and talk to their doctor about whether prostate cancer testing is right for them.
“It is important for men to know their risk and talk to their doctors so they can determine if prostate cancer testing is right for them,” said Richard A. Memo, MD, Chair of the Urology Care Foundation. “Having the tools and facts empowers individuals and their doctors to make informed decisions.”
Prostate cancer is the second most common cancer in America, affecting one in seven men. Odds increase to one in five if they are African American and one in three if they have a family history; however, the educational tools are making an impact. More men are talking with their doctors and getting tested, and fewer men are dying from the disease.
To view the multimedia release go to:
http://www.multivu.com/players/English/7365551-prostate-cancer-know-your-stats-psa/
Susan G. Komen Knoxville readies the finish line for the 2014 Race for the Cure on October 18th at World’s Fair Park.
This year’s “Do You Tutu?” theme will attract a variety of pink tutus to the race. Komen Knoxville launched this theme to bring a sense of hope and happiness to the families, supporters and survivors battling breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7313552-komen-knoxville-laces-up-for-2014-race-for-the-cure-do-you-tutu/
Cancer is the leading cause of death by disease in children from ages 1 to 19 in the U.S. Yet, childhood cancer research and services are vastly and consistently underfunded. This weekend, Northwestern Mutual financial professionals and employees will support the fight against childhood cancer through its nonprofit partner, Alex’s Lemonade Stand Foundation (ALSF), by holding nearly 200 lemonade stands as part of the Foundation’s national fundraising initiative, Alex’s Lemonade Days (June 12-14).
Founded by Alex Scott (1996-2004) in 2004, Alex’s Lemonade Days is a three-day national event that grew out of Alex’s front yard lemonade stand. During Alex’s Lemonade Days, dedicated volunteers host thousands of Alex’s Lemonade Stands across the country, raising more than $1 million for childhood cancer research. June 2015 will mark the 12th Annual Lemonade Days, and will continue Alex’s mission to raise money one cup of lemonade at a time, renewing her idea that any contributor, at any age, can make a difference.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7422153-northwestern-mutual-lemonade-days/
NFL PLAY 60, the National Football League’s youth health and fitness campaign, is the new “Official Champion of Play” at St. Jude Children’s Research Hospital®, the global leader in finding cures and saving children with cancer and other deadly diseases.
To commemorate this new milestone in the ongoing partnership between the NFL and St. Jude, a St. Jude patient will join NFL commissioner Roger Goodell on stage to announce a pick during the first round of the 2013 NFL Draft. The NFL Network and ESPN will televise live coverage of the NFL Draft beginning at 8 p.m. EST on Thursday, April 25.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58566-st-jude-children-s-research-hospital-nfl-play-60
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
The Prostate Cancer Foundation is throwing a one-two punch to knock out prostate cancer for good with the recent production of a public service announcement featuring boxing legend and five-time heavyweight champion of the world Evander Holyfield. The message encourages African-American men to get regularly checked for prostate cancer because they are more than twice as likely to develop this disease than any other type of cancer.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7545851-pcf-holyfield-prostate-cancer-psa/
